trifluridine and tipiracil

DRUG2 trials

Conditions

Circulating Tumor DNAColorectal Cancer (CRC)Colorectal NeoplasmsTrifluridine and Tipiracil

Phase 3

Initial Attack on Latent Metastasis Using TAS-102 for ct DNA Identified Colorectal Cancer Patients After Curative Resection

CompletedNCT04457297

National Cancer Center Hospital EastCirculating Tumor DNA, Colorectal Neoplasms, Trifluridine and Tipiracil

Start: 2020-07-08End: 2024-07-18Updated: 2026-01-21

Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation

CompletedNCT05198934

AmgenColorectal Cancer (CRC)

Start: 2022-04-19End: 2026-04-14Updated: 2026-07-22

Nature Medicine2026-06-08

Circulating tumor DNA (ctDNA) clearance as an early indicator of sotorasib + panitumumab efficacy and prognosis in KRAS G12C–mutated colorectal cancer (mCRC): Results from phase 3 CodeBreaK 300.

Journal of Clinical Oncology2026-05-27

Impact of postsurgical circulating tumor DNA (ctDNA) dynamics on eligibility of colorectal cancer (CRC) patients for randomized ALTAIR trial: Implications for treat-on-molecular-recurrence (TOMR) trials.

Journal of Clinical Oncology2026-05-27

Impact of postoperative ctDNA dynamics on eligibility for the ALTAIR randomized trial in patients with colorectal cancer: Implications for clinical trial enrollment.

Journal of Clinical Oncology2026-01-10

Post-hoc central radiological review of the ALTAIR study in patients with molecular residual disease (MRD) following curative resection of colorectal cancer (CRC).

Journal of Clinical Oncology2026-01-10

2025-08-111 citations

Long-term safety and efficacy of sotorasib plus panitumumab and FOLFIRI for previously treated KRAS G12C-mutated metastatic colorectal cancer (mCRC): CodeBreaK 101 (phase 1b).

Journal of Clinical Oncology2025-05-284 citations

Biomarkers of emergent resistance to sotorasib plus panitumumab in KRAS G12C-mutated metastatic colorectal cancer (mCRC) from the randomized, phase 3 CodeBreaK 300 study.

Journal of Clinical Oncology2025-05-281 citations

Ethnic disparities in clinical trials for FDA-approved drugs in colon cancer: A post-COVID era analysis (2020-2024).

Journal of Clinical Oncology2025-05-28

Abstract 1120: Baseline biomarker analyses of patients with chemorefractory KRAS G12C-mutated metastatic colorectal cancer (mCRC) from the phase 3 CodeBreaK 300 study

Cancer Research2025-04-21

A randomized, double-blind, phase III study comparing trifluridine/tipiracil (FTD/TPI) versus placebo in patients with molecular residual disease following curative resection of colorectal cancer (CRC): The ALTAIR study.

Journal of Clinical Oncology2025-01-278 citations

A phase 3 study of first-line sotorasib, panitumumab, and FOLFIRI versus FOLFIRI with or without bevacizumab-awwb for patients with KRAS G12C–mutated metastatic colorectal cancer (CodeBreaK 301).

Journal of Clinical Oncology2025-01-272 citations

The FACT-GP5 as a global tolerability measure: responsiveness and robustness to missing assessments.

2024-07-243 citations

Overall survival (OS) of phase 3 CodeBreaK 300 study of sotorasib plus panitumumab (soto+pani) versus investigator’s choice of therapy for KRAS G12C-mutated metastatic colorectal cancer (mCRC).

Journal of Clinical Oncology2024-06-0513 citations

Journal of Clinical Oncology2024-01-202 citations

New Treatment for Metastatic Colorectal Cancer With Mutated KRAS G12C

Oncology Times2024-01-01

Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C

New England Journal of Medicine2023-10-22288 citations

A randomized, double-blind, phase III study comparing trifluridine/tipiracil hydrochloride therapy versus placebo in resected colorectal cancer patients who are positive for blood circulating tumor DNA after standard adjuvant therapy (EPOC 1905): ALTAIR trial in CIRCULATE-Japan (trial in progress).

Journal of Clinical Oncology2022-01-199 citations

trifluridine and tipiracil

Sponsors

Conditions

Phase 3

Related Papers